Clinical Trials on Primary Systemic Amyloidosis

Total 224651 results

PETHEMA Foundation

Completed

Lendexal in Patients With Primary Systemic Amyloidosis (AL) Newly Diagnosed (LENDEXAL)

Primary Systemic Amyloidosis

Spain
National Cancer Institute (NCI)

Terminated

Iododoxorubicin in Treating Patients With Primary Systemic Amyloidosis

Primary Systemic Amyloidosis

United States
University Hospital, Limoges
Ministry of Health, France

Completed

Intensive Versus Conventional Treatment in Patients With Primary Amyloidosis

Primary Systemic Amyloidosis (AL)

France
Mayo Clinic

Completed

Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic Light Chain Amyloidosis

Primary Systemic Amyloidosis

United States
National Cancer Institute (NCI)

Completed

Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic Light-Chain Amyloidosis

Primary Systemic Amyloidosis | Light Chain Deposition Disease

United States
M.D. Anderson Cancer Center
Takeda; Janssen Pharmaceuticals

Active, not recruiting

Daratumumab, Ixazomib, and Dexamethasone in AL Amyloidosis

Recurrent Primary Amyloidosis | Refractory Primary Amyloidosis | Newly Diagnosed Primary Amyloidosis

United States
The Cleveland Clinic

Completed

Phase II Trial of Enbrel in Patients With Primary Systemic Amyloidosis

Primary Systemic Amyloidosis
Medical College of Wisconsin
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Doxycycline to Upgrade Organ Response in Light Chain (AL) Amyloidosis Trial (DUAL)

Primary Systemic Amyloidosis

United States
Chulalongkorn University

Unknown

Efficacy of Methylene Blue Mediated Photodynamic Therapy for Primary Localized Cutaneous Amyloidosis Treatment in Asians

Lichen Amyloidosis

Thailand
Prothena Biosciences Ltd.

Terminated

The VITAL Amyloidosis Study, a Global Phase 3, Efficacy and Safety Study of NEOD001 in Patients With AL Amyloidosis (VITAL)

Primary Systemic (AL) Amyloidosis

United States, Spain, Israel, Canada, Poland, Netherlands, France, Germany, United Kingdom, Belgium, Denmark, Greece, Australia, Austria, Italy
Alnylam Pharmaceuticals

Completed

ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)

Amyloid Neuropathies | Amyloid Neuropathies, Familial | Amyloidosis, Hereditary | Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC) | Amyloidosis, Hereditary, Transthyretin-Related | Familial Transthyretin Cardiac Amyloidosis

United States, France, Italy, Spain, Canada, Germany, Belgium, Sweden, United Kingdom
Alnylam Pharmaceuticals

Completed

The Study of an Investigational Drug, Revusiran (ALN-TTRSC), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Whose Disease Has Continued to Worsen Following Liver Transplant

ATTR Amyloidosis | Transthyretin (TTR)-Mediated Amyloidosis | Familial Amyloidotic Polyneuropathy (FAP) | Familial Amyloid Neuropathies

France, Germany, Portugal, United Kingdom, Sweden, Spain
University of Tennessee
FDA Office of Orphan Products Development

Completed

Radioimmunoimaging of AL Amyloidosis

Primary Amyloidosis

United States
Barbara Ann Karmanos Cancer Institute
Bristol-Myers Squibb; National Cancer Institute (NCI); Multiple Myeloma Research...

Active, not recruiting

Lenalidomide, Dexamethasone, and Elotuzumab With or Without Cyclophosphamide in Treating Patients With Relapsed Primary Amyloidosis

Recurrent Primary Amyloidosis

United States
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Terminated

First-line Pomalidomide, Bortezomib, and Dexamethasone For AL Amyloidosis or LCDD

Primary Systemic Amyloidosis | Light Chain Deposition Disease

United States, Canada
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Completed

Bortezomib, Melphalan, and Dexamethasone in Treating Patients With Primary Amyloidosis or Light Chain Deposition Disease

Primary Systemic Amyloidosis | Light Chain Deposition Disease

United States
Mayo Clinic

Completed

Efficacy of CC-5013 (Revlimid or Lenalidomide) in Patients With Primary Systemic Amyloidosis

Amyloidosis

United States
Alnylam Pharmaceuticals

Completed

DISCOVERY: A Study Examining the Prevalence of TTR Mutations in Subjects Suspected of Having Cardiac Amyloidosis

Familial Amyloidotic Cardiomyopathy (FAC)

United States, France, Spain, United Kingdom, Belgium, Brazil
SWOG Cancer Research Network
National Cancer Institute (NCI)

Active, not recruiting

S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis

Nausea | Constipation | Diarrhea | Purpura | Lymphadenopathy | Gastrointestinal Hemorrhage | Hepatomegaly | Primary Systemic Amyloidosis | Amorphous, Eosinophilic, and Acellular Deposit | Early Satiety | Macroglossia | Recurrent Primary Amyloidosis | Refractory Primary Amyloidosis

United States
Criterium, Inc.
Amgen

Completed

A Safety Study of Carfilzomib in Patients With Previously-Treated Systemic Light Chain Amyloidosis

Amyloidosis | Systemic Light Chain Amyloidosis

United States
IRCCS Policlinico S. Matteo

Terminated

Epigallocatechingallate (EGCG) in Cardiac AL Amyloidosis (EpiCardiAL)

Primary Amyloidosis of Light Chain Type

Italy
IRCCS Policlinico S. Matteo

Completed

Pomalidomide and Dexamethasone (PDex) in AL Amyloidosis

Primary Amyloidosis of Light Chain Type

Italy
Chulalongkorn University
Ratchadapiseksompotch Fund

Unknown

Efficacy of 308-nm Excimer Laser for Primary Localized Cutaneous Amyloidosis Treatment in Asians

Lichen Amyloidosis

Thailand
University of Tennessee Graduate School of Medicine
Attralus, Inc.

Recruiting

A Phase 1 Study of 99mTc-p5+14 in Healthy Volunteers and Patients With AL or ATTR Systemic Amyloidosis

Systemic Amyloidosis

United States
University of Tennessee Graduate School of Medicine

Completed

124I-p5+14 Injection Safety in Subjects With Systemic Amyloidosis

Systemic Amyloidosis

United States
Peking Union Medical College Hospital
Xian-Janssen Pharmaceutical Ltd.

Active, not recruiting

Daratumumab Combined With Bortezomib and Dexamethasone in Mayo 04 Stage III Light Chain Amyloidosis

Amyloidosis; Systemic

China
Jin Lu, MD

Recruiting

Bortezomib, Pomalidomide, Dexamethasone For Systemic AL Amyloidosis

Systemic Amyloidosis

China
Midwest Heart & Vascular Specialists

Recruiting

Amyloidosis Incidence in High-Risk Cardiac Device Patients

AL Amyloidosis | Amyloid | Cardiac Amyloidosis | Amyloidosis Cardiac | Systemic Amyloidosis | ATTR Amyloidosis Wild Type | Infiltrative Cardiomyopathy, Amyloid

United States
Prothena Biosciences Ltd.

Completed

Phase 1/2, Open Label, Dose Escalation Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis

Primary Amyloidosis

United States
Heidelberg University
Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH

Completed

A Trial of Treatment With Lenalidomide-Melphalan-Dexamethasone in Patients With Primary (AL) Amyloidosis (LEOMEX)

Primary Amyloidosis

Germany
Steen Hvitfeldt Poulsen

Recruiting

Prevalence of wtATTR-CM After Carpal Tunnel Release Surgery (CACTuS2)

Transthyretin Amyloidosis | Transthyretin Cardiac Amyloidosis | Wild-Type Transthyretin-Related (ATTR)Amyloidosis

Denmark
Stanford University

Withdrawn

Mixed Chimeric Transplantation for Primary Amyloidosis

Amyloidosis
Jian Li
Peking University First Hospital; Tongji Hospital; Nanfang Hospital of Southern... and other collaborators

Completed

BCD With or Without Doxycycline in Mayo Stage II-III Light Chain Amyloidosis Patients

Amyloidosis; Systemic

China
Stanford University

Completed

Autologous Stem Cell Rescue for Primary Amyloidosis

Amyloidosis | Blood and Marrow Transplant (BMT)

United States
Attralus, Inc.
Novotech (Australia) Pty Limited

Recruiting

A Study of AT-02 in Subjects With Systemic Amyloidosis.

Amyloidosis; Systemic

United States, Australia, United Kingdom
University of Tennessee Graduate School of Medicine

Active, not recruiting

Repeat PET/CT Imaging of Patients With Amyloid 124I-AT-01 to Measure Changes in Organ-specific Amyloid Load

Systemic Amyloidosis

United States
IRCCS Policlinico S. Matteo

Withdrawn

High Cut-off Hemodialysis in Patients With Advanced Cardiac AL Amyloidosis and End Stage Renal Disease (DIACAL)

Primary Amyloidosis of Light Chain Type

Italy
Austin Neuromuscular Center
Alnylam Pharmaceuticals

Recruiting

Spectrum of Peripheral and Autonomic Neuropathies in Patients With aTTRwt Amyloidosis and Response to Patisiran Therapy

Polyneuropathies | Transthyretin Amyloidosis | Wild-Type Transthyretin-Related (ATTR)Amyloidosis | Wild-Type Transthyretin Cardiac Amyloidosis | Wild Type ATTR Amyloidosis

United States
Attralus, Inc.
Novotech (Australia) Pty Limited

Recruiting

Study of AT-02 in Healthy Volunteers and Subjects With Systemic Amyloidosis (AT02-001)

Amyloidosis; Systemic

United States, Australia
Margarida Magalhaes-Silverman
National Cancer Institute (NCI)

Completed

Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Primary Systemic Amyloidosis | Light Chain Deposition Disease | Extramedullary Plasmacytoma | Isolated Plasmacytoma of Bone

United States
Jin Lu, MD

Recruiting

Optimize First-line Treatment for AL Amyloidosis With t (11; 14)

AL Amyloidosis | Amyloidosis; Systemic

China
Tufts Medical Center

Completed

Minimal Residual Disease as a Possible Predictive Factor for Relapse in Patients With AL Amyloidosis

Amyloidosis | Primary Amyloidosis

United States
Takeda

Terminated

Study of Dexamethasone Plus IXAZOMIB (MLN9708) or Physicians Choice of Treatment in Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis

Relapsed or Refractory Systemic Light Chain Amyloidosis

United States, Canada, Spain, Israel, France, Australia, Denmark, Germany, Korea, Republic of, Greece, Netherlands, Brazil, Czechia, Italy, United Kingdom
Boston Medical Center
Spectrum Pharmaceuticals, Inc

Terminated

Propylene Glycol-Free Melphalan Hydrochloride (Evomela) in AL Amyloidosis Patients

Amyloidosis; Systemic

United States
Boston Medical Center

Completed

Melphalan, Lenalidomide, and Dexamethasone in Treating Patients With Primary Systemic Amyloidosis (MRD)

Multiple Myeloma

United States
Southwest Oncology Group
National Cancer Institute (NCI); Cancer and Leukemia Group B

Completed

S9628 Dexamethasone Plus Interferon Alfa in Treating Patients With Primary Systemic Amyloidosis

Multiple Myeloma

United States
Selayang Hospital

Completed

A Randomised, Open-Label, Cross Over Group, Single-Centre Controlled Study To Evaluate The Clinical Performance Of Medium Cut-Off Membrane Dialyser Compared With High Flux Dialyser Among Patients With Chronic Haemodialysis (HD-1)

Quality of Life | Dialysis Amyloidosis | Hemodialysis-Associated Amyloidosis

Malaysia
Millennium Pharmaceuticals, Inc.

Completed

Study of Oral Ixazomib in Adult Participants With Relapsed or Refractory Light Chain Amyloidosis

Light-Chain Amyloidosis

United States, Canada, France, Germany, Italy
Boston University
Corino Therapeutics, Inc.

Completed

Short-term Effects of TOLCAPONE on Transthyretin Stability in Subjects With Leptomeningeal TTR Amyloidosis (ATTR)

Transthyretin Amyloidosis | Amyloidosis, Leptomeningeal, Transthyretin-Related

United States
Wuhan Union Hospital, China

Recruiting

The Diagnostic Value of Hybrid PET/MR for Systemic Amyloidosis

PET/MR | Systemic Amyloidosis

China

Clinical Trials on Primary Systemic Amyloidosis

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Congo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations